IL319242A - Dosage regimens of estrogen receptor degraders - Google Patents

Dosage regimens of estrogen receptor degraders

Info

Publication number
IL319242A
IL319242A IL319242A IL31924225A IL319242A IL 319242 A IL319242 A IL 319242A IL 319242 A IL319242 A IL 319242A IL 31924225 A IL31924225 A IL 31924225A IL 319242 A IL319242 A IL 319242A
Authority
IL
Israel
Prior art keywords
estrogen receptor
dosage regimens
receptor degraders
degraders
regimens
Prior art date
Application number
IL319242A
Other languages
Hebrew (he)
Inventor
Ronald Peck
Sheryl Maxine Gough
John J Flanagan
Sibyl Anderson
Ian Charles Anthony Taylor
Julia Perkins Smith
Weiwei Tan
Original Assignee
Arvinas Operations Inc
Pfizer
Ronald Peck
Sheryl Maxine Gough
John J Flanagan
Sibyl Anderson
Ian Charles Anthony Taylor
Julia Perkins Smith
Weiwei Tan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc, Pfizer, Ronald Peck, Sheryl Maxine Gough, John J Flanagan, Sibyl Anderson, Ian Charles Anthony Taylor, Julia Perkins Smith, Weiwei Tan filed Critical Arvinas Operations Inc
Publication of IL319242A publication Critical patent/IL319242A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL319242A 2022-08-31 2023-08-30 Dosage regimens of estrogen receptor degraders IL319242A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263402651P 2022-08-31 2022-08-31
US202363443892P 2023-02-07 2023-02-07
US202363454422P 2023-03-24 2023-03-24
US202363454485P 2023-03-24 2023-03-24
US202363508503P 2023-06-15 2023-06-15
PCT/US2023/031574 WO2024049926A1 (en) 2022-08-31 2023-08-30 Dosage regimens of estrogen receptor degraders

Publications (1)

Publication Number Publication Date
IL319242A true IL319242A (en) 2025-04-01

Family

ID=88192329

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319242A IL319242A (en) 2022-08-31 2023-08-30 Dosage regimens of estrogen receptor degraders

Country Status (10)

Country Link
EP (1) EP4580631A1 (en)
JP (1) JP2025530742A (en)
KR (1) KR20250076543A (en)
CN (1) CN120112291A (en)
AU (1) AU2023336057A1 (en)
CA (1) CA3266061A1 (en)
IL (1) IL319242A (en)
MX (1) MX2025002284A (en)
TW (2) TW202539669A (en)
WO (1) WO2024049926A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN119258223A (en) * 2023-07-06 2025-01-07 海创药业股份有限公司 A combined drug for degrading estrogen receptors and its use
WO2026044127A1 (en) * 2024-08-22 2026-02-26 Arvinas Operations, Inc. Administration of cyp3a inhibitors in the treatment of cancer
WO2026128391A1 (en) * 2024-12-09 2026-06-18 Arvinas Operations, Inc. Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
DE602004017474D1 (en) 2003-07-11 2008-12-11 Warner Lambert Co ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR
TWI398252B (en) 2006-05-26 2013-06-11 諾華公司 Pyrrolopyrimidine compound and use thereof
KR20090052385A (en) 2006-09-08 2009-05-25 화이자 프로덕츠 인크. Synthesis of 2- (pyridin-2-ylamino) -pyrido [2,3-D] pyrimidin-7-one
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (en) 2008-12-22 2010-07-27 Lilly Co Eli PROTEIN CINASE INHIBITORS
AR083797A1 (en) 2010-11-10 2013-03-20 Novartis Ag DIMETHYL ACID SUCCINATE 7-CYCLOPENTIL-2- (5-PIPERAZIN-1-IL-PIRIDIN-2-IL-AMINO) -7H-PIRROLO- [2,3-D] PIRIMIDIN-6-CARBOXILICO, PROCESS FOR PREPARE IT, INTERMEDIARIES OF SUCH SYNTHESIS AND PREPARATION PROCESS OF THE SAME
DK3431475T3 (en) 2013-02-21 2021-05-25 Pfizer Solid forms of a selective CDK4 / 6 inhibitor
SI4197530T1 (en) 2015-04-16 2026-03-31 Novartis Ag RIBOCYCLIB TABLET
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
IL303143A (en) * 2020-12-14 2023-07-01 Arvinas Operations Inc Methods for treating cancer with tetrahydronaphthalene derivatives as estrogen receptor antagonists

Also Published As

Publication number Publication date
CA3266061A1 (en) 2024-03-07
AU2023336057A1 (en) 2025-03-27
EP4580631A1 (en) 2025-07-09
TW202416991A (en) 2024-05-01
WO2024049926A1 (en) 2024-03-07
CN120112291A (en) 2025-06-06
TW202539669A (en) 2025-10-16
KR20250076543A (en) 2025-05-29
MX2025002284A (en) 2025-06-02
TWI866427B (en) 2024-12-11
JP2025530742A (en) 2025-09-17

Similar Documents

Publication Publication Date Title
CA3266061A1 (en) Dosage regimens of estrogen receptor degraders
GB2595776B (en) Therapeutic solid dosage forms
IL308389A (en) Dosage regimens for ecubectedin
IL295598A (en) Selective estrogen receptor degraders
PL4370116T3 (en) Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
SG11202100145YA (en) Selective estrogen receptor degraders
ZA202201157B (en) Selective estrogen receptor degrader
IL320859A (en) Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)
IL315886A (en) Dosage regimens for anti-cd19 agents and uses thereof
IL313886A (en) Processes for the preparation of selective estrogen receptor degraders
CA3295229A1 (en) Solid oral dosage forms of estrogen receptor degraders
GB202004115D0 (en) Modified release formulations and dosage regimens
CA3274497A1 (en) Dosage forms of an estrogen receptor antagonist
IL315178A (en) Dosage regimen
IL304354A (en) Solid tablet dosage form of ridinilazole
EP3932490A4 (en) ANTIPRURITIOUS AGENT USING A PAC1 RECEPTOR ANTAGONIST
EP4310079A4 (en) ESTROGEN RECEPTOR ANTAGONIST
HK40108270A (en) Dosage regimens for ecubectedin
LT3277278T (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
CA3288633A1 (en) Advantageous human dosage regimens for administration of inx-315
GB2621351B (en) Metered dosage apparatus
IL325443A (en) Combination therapy for amelioration of side effects of estrogen receptor inhibitor treatment
HK40087442A (en) Preparation of an selective estrogen receptor degrader
HK40105571A (en) Dosage regimens for parp7 inhibitors
GB202209299D0 (en) Dosage regimen for antiviral therapy